PL3041472T3 - Chinolinokarboksyamidy do stosowania w leczeniu szpiczaka mnogiego - Google Patents
Chinolinokarboksyamidy do stosowania w leczeniu szpiczaka mnogiegoInfo
- Publication number
- PL3041472T3 PL3041472T3 PL15763622T PL15763622T PL3041472T3 PL 3041472 T3 PL3041472 T3 PL 3041472T3 PL 15763622 T PL15763622 T PL 15763622T PL 15763622 T PL15763622 T PL 15763622T PL 3041472 T3 PL3041472 T3 PL 3041472T3
- Authority
- PL
- Poland
- Prior art keywords
- treatment
- multiple myeloma
- quinoline carboxamides
- carboxamides
- quinoline
- Prior art date
Links
- 208000034578 Multiple myelomas Diseases 0.000 title 1
- 206010035226 Plasma cell myeloma Diseases 0.000 title 1
- ZEXKKIXCRDTKBF-UHFFFAOYSA-N quinoline-2-carboxamide Chemical class C1=CC=CC2=NC(C(=O)N)=CC=C21 ZEXKKIXCRDTKBF-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14185892 | 2014-09-23 | ||
| EP15763622.6A EP3041472B1 (en) | 2014-09-23 | 2015-09-18 | Quinoline carboxamides for use in the treatment of multiple myeloma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3041472T3 true PL3041472T3 (pl) | 2017-08-31 |
Family
ID=51660309
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL15763622T PL3041472T3 (pl) | 2014-09-23 | 2015-09-18 | Chinolinokarboksyamidy do stosowania w leczeniu szpiczaka mnogiego |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US9956212B2 (enExample) |
| EP (1) | EP3041472B1 (enExample) |
| JP (1) | JP6647287B2 (enExample) |
| KR (1) | KR102533033B1 (enExample) |
| CN (1) | CN107108510B (enExample) |
| AU (1) | AU2015316824B2 (enExample) |
| CA (1) | CA2961978C (enExample) |
| EA (1) | EA030948B1 (enExample) |
| ES (1) | ES2631194T3 (enExample) |
| IL (1) | IL251043B (enExample) |
| MX (1) | MX366837B (enExample) |
| NZ (1) | NZ730816A (enExample) |
| PL (1) | PL3041472T3 (enExample) |
| WO (1) | WO2016042112A1 (enExample) |
| ZA (1) | ZA201702377B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA030948B1 (ru) * | 2014-09-23 | 2018-10-31 | Эктив Байотек Аб | Хинолинкарбоксамиды для применения в лечении множественной миеломы |
| CN115209881A (zh) * | 2020-03-03 | 2022-10-18 | 活跃生物技术有限公司 | 用于组合疗法的他喹莫德或其药学上可接受的盐 |
| EP4582448A3 (en) * | 2020-07-23 | 2025-12-10 | Erasmus University Rotterdam Medical Center | S100 proteins as novel therapeutic targets in myeloproliferative neoplasms |
| WO2022152902A1 (en) | 2021-01-18 | 2022-07-21 | Active Biotech Ab | Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome |
| PL4346773T3 (pl) | 2021-05-25 | 2025-11-03 | Active Biotech Ab | Duża liczba cząstek taskwinimodu i ich zastosowanie |
| KR20240029029A (ko) | 2021-07-02 | 2024-03-05 | 액티브 바이오테크 에이비 | 타스퀴니모드를 함유한 약학적 제품 및 이러한 제품의 순도 평가 방법 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9801474D0 (sv) | 1998-04-27 | 1998-04-27 | Active Biotech Ab | Quinoline Derivatives |
| SE9802549D0 (sv) | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
| RS51019B (sr) * | 1999-10-25 | 2010-10-31 | Active Biotech Ab. | Lekovi za lečenje malignih tumora |
| SE0002320D0 (sv) * | 1999-10-25 | 2000-06-21 | Active Biotech Ab | Malignant tumors |
| SE0201778D0 (sv) | 2002-06-12 | 2002-06-12 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
| SE0400235D0 (sv) | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
| US9469876B2 (en) * | 2010-04-06 | 2016-10-18 | Caris Life Sciences Switzerland Holdings Gmbh | Circulating biomarkers for metastatic prostate cancer |
| EP2590949B1 (en) | 2010-07-09 | 2015-11-25 | Active Biotech AB | Method for manufacturing of quinoline-3-carboxamides |
| JP2013540995A (ja) * | 2010-08-18 | 2013-11-07 | カリス ライフ サイエンシズ ルクセンブルク ホールディングス エス．アー．エール．エル． | 疾患に対する循環バイオマーカー |
| WO2012034543A1 (es) | 2010-09-13 | 2012-03-22 | Universidad De Costa Rica | Conector estructural para bambú |
| FR2967353B1 (fr) * | 2010-11-16 | 2013-08-16 | Centre Nat Rech Scient | Derives de quinolinone |
| EP2537517A1 (en) * | 2011-06-22 | 2012-12-26 | Active Biotech AB | Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide |
| EA030948B1 (ru) * | 2014-09-23 | 2018-10-31 | Эктив Байотек Аб | Хинолинкарбоксамиды для применения в лечении множественной миеломы |
-
2015
- 2015-09-18 EA EA201790687A patent/EA030948B1/ru not_active IP Right Cessation
- 2015-09-18 WO PCT/EP2015/071391 patent/WO2016042112A1/en not_active Ceased
- 2015-09-18 AU AU2015316824A patent/AU2015316824B2/en active Active
- 2015-09-18 CN CN201580051397.XA patent/CN107108510B/zh active Active
- 2015-09-18 US US15/510,728 patent/US9956212B2/en active Active
- 2015-09-18 EP EP15763622.6A patent/EP3041472B1/en active Active
- 2015-09-18 JP JP2017513751A patent/JP6647287B2/ja active Active
- 2015-09-18 MX MX2017003294A patent/MX366837B/es active IP Right Grant
- 2015-09-18 CA CA2961978A patent/CA2961978C/en active Active
- 2015-09-18 NZ NZ730816A patent/NZ730816A/en unknown
- 2015-09-18 PL PL15763622T patent/PL3041472T3/pl unknown
- 2015-09-18 KR KR1020177010510A patent/KR102533033B1/ko active Active
- 2015-09-18 ES ES15763622.6T patent/ES2631194T3/es active Active
-
2017
- 2017-03-09 IL IL251043A patent/IL251043B/en active IP Right Grant
- 2017-04-04 ZA ZA2017/02377A patent/ZA201702377B/en unknown
-
2018
- 2018-04-06 US US15/947,279 patent/US10314836B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3041472B1 (en) | 2017-02-01 |
| MX366837B (es) | 2019-07-26 |
| EA030948B1 (ru) | 2018-10-31 |
| ZA201702377B (en) | 2018-08-29 |
| EA201790687A1 (ru) | 2017-08-31 |
| CN107108510B (zh) | 2020-10-23 |
| CA2961978A1 (en) | 2016-03-24 |
| IL251043A0 (en) | 2017-04-30 |
| KR20170052691A (ko) | 2017-05-12 |
| KR102533033B1 (ko) | 2023-05-15 |
| ES2631194T3 (es) | 2017-08-29 |
| US10314836B2 (en) | 2019-06-11 |
| JP6647287B2 (ja) | 2020-02-14 |
| MX2017003294A (es) | 2017-06-23 |
| BR112017004947A2 (pt) | 2017-12-05 |
| US20180228794A1 (en) | 2018-08-16 |
| NZ730816A (en) | 2022-01-28 |
| AU2015316824B2 (en) | 2020-10-29 |
| JP2017528473A (ja) | 2017-09-28 |
| WO2016042112A1 (en) | 2016-03-24 |
| US9956212B2 (en) | 2018-05-01 |
| AU2015316824A1 (en) | 2017-04-27 |
| EP3041472A1 (en) | 2016-07-13 |
| CN107108510A (zh) | 2017-08-29 |
| US20170273967A1 (en) | 2017-09-28 |
| CA2961978C (en) | 2023-03-14 |
| IL251043B (en) | 2020-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL249481A0 (en) | Difluoromethyl-indanyl-nicotinic carboxamides | |
| IL248856B (en) | New treatment | |
| HUE061672T2 (hu) | Glikán-interakcióban lévõ vegyületek és felhasználási módszerek | |
| LT3089971T (lt) | Junginiai ir panaudojimo būdai | |
| HUE051924T2 (hu) | Hõkezelési eljárás | |
| GB201401430D0 (en) | Treatment process | |
| IL251904B (en) | Epilimod for use in the treatment of melanoma | |
| ZA201702377B (en) | Quinoline carboxamides for use in the treatment of multiple myeloma | |
| GB201416832D0 (en) | Methods of treatment | |
| IL252174B (en) | Quinoline carboxamides for use in the treatment of leukemia | |
| SG11201702700UA (en) | Methods for the treatment of peri-implantitis | |
| IL252707B (en) | Compositions and methods for treating diseases | |
| GB201411027D0 (en) | Treatment | |
| GB201412010D0 (en) | Treatment of hypertransaminasemia | |
| GB201400311D0 (en) | Treating Susceptibility | |
| GB201412411D0 (en) | Treatment | |
| GB201418541D0 (en) | Materials for use with general hyperthermia treatment | |
| GB201403697D0 (en) | Compounds and methods of use | |
| GB201417719D0 (en) | New treatment | |
| GB201408384D0 (en) | New treatment | |
| GB201413317D0 (en) | Atheroscierosis treatment | |
| GB201412410D0 (en) | Treatment | |
| GB201400235D0 (en) | Treatment | |
| GB201400239D0 (en) | Treatment | |
| GB201400240D0 (en) | Treatment |